Replacement fluids in plasmapheresis : cross-over comparative study
To compare the tolerance and the cost of three replacement fluids in plasmapheresis: albumin 4% alone, albumin 4% + dextran 40, or albumin 4% + hydroxyethylstarch 6%. A one center randomized, cross-over, comparative study designed to explore the tolerance and the colloid oncotic pressure in patients...
Gespeichert in:
| Veröffentlicht in: | Intensive care medicine 1997-03, Vol.23 (3), p.342-344 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 344 |
|---|---|
| container_issue | 3 |
| container_start_page | 342 |
| container_title | Intensive care medicine |
| container_volume | 23 |
| creator | LE CONTE, P NICOLAS, F ADJOU, C N'GUYEN, J. M BILLAUD, E MOREAU, P |
| description | To compare the tolerance and the cost of three replacement fluids in plasmapheresis: albumin 4% alone, albumin 4% + dextran 40, or albumin 4% + hydroxyethylstarch 6%.
A one center randomized, cross-over, comparative study designed to explore the tolerance and the colloid oncotic pressure in patients undergoing plasmapheresis.
225 plasmapheresis procedures were performed in 27 patients.
Hemodynamic tolerance was good in the three treatment groups. Serum protein concentration after plasmapheresis was significantly lower in the albumin + hydroxyethylstarch group, followed by albumin + dextran 40, versus albumin alone. Colloid oncotic pressure before and after exchange was similar in the three groups.
The clinical use of 25-30% of hydroxyethylstarch 6% or dextran 40 with albumin 4% was clinically well tolerated and associated with a 12% decrease of the cost of substitution solutions. |
| doi_str_mv | 10.1007/s001340050338 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_78907303</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2656775621</sourcerecordid><originalsourceid>FETCH-LOGICAL-c378t-918a863a8d7350e653201e82f0f6985623517b7ba62c997894a77aa10f19f6d3</originalsourceid><addsrcrecordid>eNp90UtLw0AQB_BFlFqrR49CQBEv0dmd7MubFF9QEKT3sE02GMnL3aTQb-_WhoIePA3s_HZg_kPIOYVbCiDvPADFBIADojogU5ogiylDdUimgAmLE5GwY3Li_WeQUnA6IRMNChnqKZm_264yma1t00dFNZS5j8omCm--Nt2HddaXPrqPMtd6H7dr66KsrTvjTF-ubeT7Id-ckqPCVN6ejXVGlk-Py_lLvHh7fp0_LOIMpepjTZVRAo3KJXKwgiMDahUroBBaccGQU7mSKyNYprVUOjFSGkOhoLoQOc7I9W5s59qvwfo-rUuf2aoyjW0Hn4YfIDGkMCM3_8JtOBQUCBno5R_62Q6uCVukFCijwClXQcU79ZOCs0XaubI2bhNQuj1C-usIwV-MU4dVbfO9HlMP_auxb3xmqsKZJiv9njEByKXAb76mi0o</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1012105158</pqid></control><display><type>article</type><title>Replacement fluids in plasmapheresis : cross-over comparative study</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>LE CONTE, P ; NICOLAS, F ; ADJOU, C ; N'GUYEN, J. M ; BILLAUD, E ; MOREAU, P</creator><creatorcontrib>LE CONTE, P ; NICOLAS, F ; ADJOU, C ; N'GUYEN, J. M ; BILLAUD, E ; MOREAU, P</creatorcontrib><description>To compare the tolerance and the cost of three replacement fluids in plasmapheresis: albumin 4% alone, albumin 4% + dextran 40, or albumin 4% + hydroxyethylstarch 6%.
A one center randomized, cross-over, comparative study designed to explore the tolerance and the colloid oncotic pressure in patients undergoing plasmapheresis.
225 plasmapheresis procedures were performed in 27 patients.
Hemodynamic tolerance was good in the three treatment groups. Serum protein concentration after plasmapheresis was significantly lower in the albumin + hydroxyethylstarch group, followed by albumin + dextran 40, versus albumin alone. Colloid oncotic pressure before and after exchange was similar in the three groups.
The clinical use of 25-30% of hydroxyethylstarch 6% or dextran 40 with albumin 4% was clinically well tolerated and associated with a 12% decrease of the cost of substitution solutions.</description><identifier>ISSN: 0342-4642</identifier><identifier>EISSN: 1432-1238</identifier><identifier>DOI: 10.1007/s001340050338</identifier><identifier>PMID: 9083239</identifier><identifier>CODEN: ICMED9</identifier><language>eng</language><publisher>Heidelberg: Springer</publisher><subject>Adult ; Aged ; Albumins - administration & dosage ; Albumins - economics ; Analysis of Variance ; Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy ; Apheresis ; Biological and medical sciences ; Blood. Blood and plasma substitutes. Blood products. Blood cells. Blood typing. Plasmapheresis. Apheresis ; Catheters ; Chi-Square Distribution ; Cross-Over Studies ; Dextrans - administration & dosage ; Dextrans - economics ; Female ; Hemodynamics ; Humans ; Hydroxyethyl Starch Derivatives - administration & dosage ; Hydroxyethyl Starch Derivatives - economics ; Male ; Medical sciences ; Middle Aged ; Patients ; Plasma ; Plasma Substitutes - administration & dosage ; Plasma Substitutes - economics ; Plasmapheresis ; Prospective Studies ; Proteins ; Transfusions. Complications. Transfusion reactions. Cell and gene therapy</subject><ispartof>Intensive care medicine, 1997-03, Vol.23 (3), p.342-344</ispartof><rights>1997 INIST-CNRS</rights><rights>Springer-Verlag Berlin Heidelberg 1997</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c378t-918a863a8d7350e653201e82f0f6985623517b7ba62c997894a77aa10f19f6d3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2603576$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9083239$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>LE CONTE, P</creatorcontrib><creatorcontrib>NICOLAS, F</creatorcontrib><creatorcontrib>ADJOU, C</creatorcontrib><creatorcontrib>N'GUYEN, J. M</creatorcontrib><creatorcontrib>BILLAUD, E</creatorcontrib><creatorcontrib>MOREAU, P</creatorcontrib><title>Replacement fluids in plasmapheresis : cross-over comparative study</title><title>Intensive care medicine</title><addtitle>Intensive Care Med</addtitle><description>To compare the tolerance and the cost of three replacement fluids in plasmapheresis: albumin 4% alone, albumin 4% + dextran 40, or albumin 4% + hydroxyethylstarch 6%.
A one center randomized, cross-over, comparative study designed to explore the tolerance and the colloid oncotic pressure in patients undergoing plasmapheresis.
225 plasmapheresis procedures were performed in 27 patients.
Hemodynamic tolerance was good in the three treatment groups. Serum protein concentration after plasmapheresis was significantly lower in the albumin + hydroxyethylstarch group, followed by albumin + dextran 40, versus albumin alone. Colloid oncotic pressure before and after exchange was similar in the three groups.
The clinical use of 25-30% of hydroxyethylstarch 6% or dextran 40 with albumin 4% was clinically well tolerated and associated with a 12% decrease of the cost of substitution solutions.</description><subject>Adult</subject><subject>Aged</subject><subject>Albumins - administration & dosage</subject><subject>Albumins - economics</subject><subject>Analysis of Variance</subject><subject>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</subject><subject>Apheresis</subject><subject>Biological and medical sciences</subject><subject>Blood. Blood and plasma substitutes. Blood products. Blood cells. Blood typing. Plasmapheresis. Apheresis</subject><subject>Catheters</subject><subject>Chi-Square Distribution</subject><subject>Cross-Over Studies</subject><subject>Dextrans - administration & dosage</subject><subject>Dextrans - economics</subject><subject>Female</subject><subject>Hemodynamics</subject><subject>Humans</subject><subject>Hydroxyethyl Starch Derivatives - administration & dosage</subject><subject>Hydroxyethyl Starch Derivatives - economics</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Patients</subject><subject>Plasma</subject><subject>Plasma Substitutes - administration & dosage</subject><subject>Plasma Substitutes - economics</subject><subject>Plasmapheresis</subject><subject>Prospective Studies</subject><subject>Proteins</subject><subject>Transfusions. Complications. Transfusion reactions. Cell and gene therapy</subject><issn>0342-4642</issn><issn>1432-1238</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1997</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp90UtLw0AQB_BFlFqrR49CQBEv0dmd7MubFF9QEKT3sE02GMnL3aTQb-_WhoIePA3s_HZg_kPIOYVbCiDvPADFBIADojogU5ogiylDdUimgAmLE5GwY3Li_WeQUnA6IRMNChnqKZm_264yma1t00dFNZS5j8omCm--Nt2HddaXPrqPMtd6H7dr66KsrTvjTF-ubeT7Id-ckqPCVN6ejXVGlk-Py_lLvHh7fp0_LOIMpepjTZVRAo3KJXKwgiMDahUroBBaccGQU7mSKyNYprVUOjFSGkOhoLoQOc7I9W5s59qvwfo-rUuf2aoyjW0Hn4YfIDGkMCM3_8JtOBQUCBno5R_62Q6uCVukFCijwClXQcU79ZOCs0XaubI2bhNQuj1C-usIwV-MU4dVbfO9HlMP_auxb3xmqsKZJiv9njEByKXAb76mi0o</recordid><startdate>19970301</startdate><enddate>19970301</enddate><creator>LE CONTE, P</creator><creator>NICOLAS, F</creator><creator>ADJOU, C</creator><creator>N'GUYEN, J. M</creator><creator>BILLAUD, E</creator><creator>MOREAU, P</creator><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M7Z</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>RC3</scope><scope>7X8</scope></search><sort><creationdate>19970301</creationdate><title>Replacement fluids in plasmapheresis : cross-over comparative study</title><author>LE CONTE, P ; NICOLAS, F ; ADJOU, C ; N'GUYEN, J. M ; BILLAUD, E ; MOREAU, P</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c378t-918a863a8d7350e653201e82f0f6985623517b7ba62c997894a77aa10f19f6d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1997</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Albumins - administration & dosage</topic><topic>Albumins - economics</topic><topic>Analysis of Variance</topic><topic>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</topic><topic>Apheresis</topic><topic>Biological and medical sciences</topic><topic>Blood. Blood and plasma substitutes. Blood products. Blood cells. Blood typing. Plasmapheresis. Apheresis</topic><topic>Catheters</topic><topic>Chi-Square Distribution</topic><topic>Cross-Over Studies</topic><topic>Dextrans - administration & dosage</topic><topic>Dextrans - economics</topic><topic>Female</topic><topic>Hemodynamics</topic><topic>Humans</topic><topic>Hydroxyethyl Starch Derivatives - administration & dosage</topic><topic>Hydroxyethyl Starch Derivatives - economics</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Patients</topic><topic>Plasma</topic><topic>Plasma Substitutes - administration & dosage</topic><topic>Plasma Substitutes - economics</topic><topic>Plasmapheresis</topic><topic>Prospective Studies</topic><topic>Proteins</topic><topic>Transfusions. Complications. Transfusion reactions. Cell and gene therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>LE CONTE, P</creatorcontrib><creatorcontrib>NICOLAS, F</creatorcontrib><creatorcontrib>ADJOU, C</creatorcontrib><creatorcontrib>N'GUYEN, J. M</creatorcontrib><creatorcontrib>BILLAUD, E</creatorcontrib><creatorcontrib>MOREAU, P</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biochemistry Abstracts 1</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Intensive care medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>LE CONTE, P</au><au>NICOLAS, F</au><au>ADJOU, C</au><au>N'GUYEN, J. M</au><au>BILLAUD, E</au><au>MOREAU, P</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Replacement fluids in plasmapheresis : cross-over comparative study</atitle><jtitle>Intensive care medicine</jtitle><addtitle>Intensive Care Med</addtitle><date>1997-03-01</date><risdate>1997</risdate><volume>23</volume><issue>3</issue><spage>342</spage><epage>344</epage><pages>342-344</pages><issn>0342-4642</issn><eissn>1432-1238</eissn><coden>ICMED9</coden><abstract>To compare the tolerance and the cost of three replacement fluids in plasmapheresis: albumin 4% alone, albumin 4% + dextran 40, or albumin 4% + hydroxyethylstarch 6%.
A one center randomized, cross-over, comparative study designed to explore the tolerance and the colloid oncotic pressure in patients undergoing plasmapheresis.
225 plasmapheresis procedures were performed in 27 patients.
Hemodynamic tolerance was good in the three treatment groups. Serum protein concentration after plasmapheresis was significantly lower in the albumin + hydroxyethylstarch group, followed by albumin + dextran 40, versus albumin alone. Colloid oncotic pressure before and after exchange was similar in the three groups.
The clinical use of 25-30% of hydroxyethylstarch 6% or dextran 40 with albumin 4% was clinically well tolerated and associated with a 12% decrease of the cost of substitution solutions.</abstract><cop>Heidelberg</cop><cop>Berlin</cop><pub>Springer</pub><pmid>9083239</pmid><doi>10.1007/s001340050338</doi><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0342-4642 |
| ispartof | Intensive care medicine, 1997-03, Vol.23 (3), p.342-344 |
| issn | 0342-4642 1432-1238 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_78907303 |
| source | MEDLINE; SpringerLink Journals |
| subjects | Adult Aged Albumins - administration & dosage Albumins - economics Analysis of Variance Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy Apheresis Biological and medical sciences Blood. Blood and plasma substitutes. Blood products. Blood cells. Blood typing. Plasmapheresis. Apheresis Catheters Chi-Square Distribution Cross-Over Studies Dextrans - administration & dosage Dextrans - economics Female Hemodynamics Humans Hydroxyethyl Starch Derivatives - administration & dosage Hydroxyethyl Starch Derivatives - economics Male Medical sciences Middle Aged Patients Plasma Plasma Substitutes - administration & dosage Plasma Substitutes - economics Plasmapheresis Prospective Studies Proteins Transfusions. Complications. Transfusion reactions. Cell and gene therapy |
| title | Replacement fluids in plasmapheresis : cross-over comparative study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T07%3A34%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Replacement%20fluids%20in%20plasmapheresis%20:%20cross-over%20comparative%20study&rft.jtitle=Intensive%20care%20medicine&rft.au=LE%20CONTE,%20P&rft.date=1997-03-01&rft.volume=23&rft.issue=3&rft.spage=342&rft.epage=344&rft.pages=342-344&rft.issn=0342-4642&rft.eissn=1432-1238&rft.coden=ICMED9&rft_id=info:doi/10.1007/s001340050338&rft_dat=%3Cproquest_cross%3E2656775621%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1012105158&rft_id=info:pmid/9083239&rfr_iscdi=true |